Comparative Results of QuantiFERON-TB Gold In-Tube and QuantiFERON-TB Gold Plus Assays for Detection of Tuberculosis Infection in Clinical Samples

The QuantiFERON-TB Gold plus (QFT-Plus) assay, an interferon gamma (IFN-gamma) release assay (IGRA), was recently introduced as the next version of the QuantiFERON-TB Gold In-Tube (OFT-61T) assay for diagnosing latent tuberculosis (TB). Whereas the QFT-GIT assay uses only one TB tube that induces a cell-mediated immune (CMI) response of CD4(+) T cells, the OFT-Plus has an additional TB antigen 2 tube (TB2) for the CMI response of CD8(+) T and CD4(+) T cells, in addition to a TB antigen 1 (TB1) tube for the CMI response of CD4(+)T cells only. We compared the results of the QFT-Plus and OFT-GIT assays as routine clinical tests for diagnosing TB. Samples from 220 patients referred for routine IGRA in various clinical departments were used. Correlations between IFN-gamma levels in the OFT-GIT and OFT-Plus assays were strong and showed good agreement (kappa value = 0.69). Seven cases with positive QFT-GIT assay results and negative OFT-Plus assay results showed IFN-gamma values near the cutoff value. However, 10 cases with active TB, recent TB, or immune problems showed discordance with the positive results only in the TB2 tube in QFT-Plus, unlike the negative results in TB1 and TB tubes. In these cases, IFN-gamma levels in the TB2 tube were significantly higher than those in other tubes. This is the first study to compare these assays as routine IGRA5 in the clinical setting. The QFT-Plus assay showed good agreement with the QFT-GIT assay and is presumably advantageous for patients with active TB, recent TB, and specific immune conditions involving CD8(+) T-cell responses.